trial

Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-2)

NCTId NCT04846881
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 611 (actual)
Sponsored by Boehringer Ingelheim
Primary completion 2024-10-18
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
611 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2021-08-24
Primary completion
2024-10-18
Eligibility
ALL · 18 Years · 50 Years

Interventions & indications

Drugs
Iclepertin

Sponsors

Boehringer IngelheimLead Sponsor

Sites

127 total
Bellflower, United StatesCosta Mesa, United StatesLong Beach, United StatesLos Angeles, United StatesOrange, United StatesTorrance, United StatesNew Haven, United StatesHialeah, United StatesMiami, United StatesWest Palm Beach, United StatesChicago, United StatesBaltimore, United States

Linked catalysts

1
Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schi — primary completion2024-10-18

Facts & assertions

4 sourced
Enrollment
611
Phase
PHASE3
Primary Completion Date
2024-10-18
Status
COMPLETED
relationships
The graph out of here
drug
Iclepertin
drug
lead_sponsor
Boehringer Ingelheim
company
indication
Schizophrenia
indication
Schizophrenia
indication